- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03084159
Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care (EPIK)
This study will use an adapted education worksheet to support patient-centered chronic kidney disease (CKD) communication, shared decision making, and patient engagement and will test its impact on intermediate patient modifiable characteristics in a primary care practice with patients who have pre-dialysis CKD.
The study team will enroll up to 100 patients with chronic kidney disease (CKD) from a primary care clinic to start. Patients will receive the intervention, which consists of the physicians using the education worksheet during appointments with patients, and patients and providers will complete surveys about its use and to measure impact on knowledge and other areas related to patient outcomes.
Once initial user testing is complete, the study team plans to submit an amendment to expand on this trial and incorporate comparison sites. This will be submitted and receive IRB approval prior to participant involvement.
The study hypothesis is that patients who receive the intervention will have greater knowledge about their CKD diagnosis, higher satisfaction with provider communication, and higher scores related to managing CKD to keep themselves healthy compared to control populations.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Amendment on 12/2018: The enrollment numbers were updated to include the control group.
Clarification 9/2021: After initial feasibility was assessed, the initial site was used additionally to enroll for the "second arm", rather than a new site as originally intended. A second site was then used for the control population.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Michigan
-
Canton, Michigan, Stati Uniti, 48187
- Canton Health Center
-
Northville, Michigan, Stati Uniti, 48168
- Northville Health Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 18 years old or older
- Have an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m2
- Able to read and understand English without an interpreter
- Diagnosed with chronic kidney disease on record
Exclusion Criteria:
- Patients with renal transplant or on dialysis
- Patients who have documented or provider known cognitive impairment or vision impairment that will prohibit meaningful interaction with education activation worksheet
- Patients who are not aware of their CKD diagnosis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione fattoriale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Participatory design and intervention
Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider.
They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment).
Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
|
Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention.
The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record.
The provider will review it with the patient during the visit.
A paper copy will print out for the patient at the end of the visit.
Altri nomi:
|
Sperimentale: Intervention Only
This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys.
Some of these providers/staff were not involved in the initial design of the intervention.
|
Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention.
The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record.
The provider will review it with the patient during the visit.
A paper copy will print out for the patient at the end of the visit.
Altri nomi:
|
Nessun intervento: Usual Care
A second site included usual care, which did not include the intervention.
Participants were given post visit surveys similar to those in the two other study / intervention arms.
This site served as a usual care comparison.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Level of objective understanding of CKD as measured by the Kidney Knowledge Survey (KiKS)
Lasso di tempo: Length of doctor's appointment, e.g., 1-2 hours
|
This will measure objective kidney disease knowledge, based on a score of 0-100, where 0 means poor level of kidney knowledge, and 100 means good level of kidney knowledge.
The KiKS was developed by Dr. Wright.
|
Length of doctor's appointment, e.g., 1-2 hours
|
Level of perceived understanding of CKD as measured by the Perceived Kidney Knowledge Survey (PiKS)
Lasso di tempo: Length of doctor's appointment, e.g., 1-2 hours
|
This will measure subjective kidney knowledge.
Score range is 1-4, where 1 is low level of perceived kidney knowledge, and 4 is high level of perceived kidney knowledge.
The PiKS was developed by Dr. Wright.
|
Length of doctor's appointment, e.g., 1-2 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Level of positive perception of patient-provider communication as measured by the Patient Communication Assessment Tool (CAT)
Lasso di tempo: Length of doctor's appointment, e.g., 1-2 hours
|
This assesses the quality of physician to patient and physician's staff to patient communication.
Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.
|
Length of doctor's appointment, e.g., 1-2 hours
|
Level of mental anxiety/stress related to condition as measured by the adapted NDBCSS scale
Lasso di tempo: Length of doctor's appointment, e.g., 1-2 hours
|
The 19-item NDBCSS (Newly Diagnosed Breast Cancer Stress Scale) is adapted to form the 21-item scale in the patient survey to measure stress associated with CKD.
The score range is 1-4, where 1 means high level of stress associated with CKD and 4 means low level of stress associated with CKD.
|
Length of doctor's appointment, e.g., 1-2 hours
|
Level of energy/fatigue and emotional well-being as measured by the SF-36 mental health component
Lasso di tempo: 4 weeks
|
The SF-36 mental health component is a 9-item scale that measures energy/fatigue and emotional well-being in the past 4 weeks.Score range is 0-100, where 0 means poor emotional well-being and low energy and 100 means good emotional well-being and high energy.
|
4 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Level of positive assessment of care as measured by the Patient Assessment of Care for Chronic Conditions (PACIC) scale
Lasso di tempo: 6 months
|
This is a 11-item scale evaluating patient assessment of the quality of care that patients received in the past 6 months.
Score range is 1-5, where 1 means poor assessment of quality of care and 5 means good assessment of quality of care.
|
6 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Julie Wright-Nunes, MD, MPH, University of Michigan
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HUM00118819
- 4K23DK097183-04 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Education worksheet
-
Tokat Gaziosmanpasa UniversityCompletatoStigmatizzazione | Funzionalità | Supporto tra pari | Disturbi mentali cronici | Formazione sulle abilità psicosociali | IntuizioneTacchino
-
Centers for Disease Control and PreventionCompletatoInfezioni da HIV | Epatite CStati Uniti
-
University of Arkansas, FayettevilleNational Cancer Institute (NCI); University of California, Los Angeles; Thomas... e altri collaboratoriAttivo, non reclutanteMalattie prevenibili da vaccino | Papilloma-virus umanoStati Uniti
-
Li-Li ChenSconosciutoDiabete mellito di tipo 2Taiwan
-
VA Office of Research and DevelopmentCompletatoIpertensioneStati Uniti
-
Wake Forest University Health SciencesNational Center for Complementary and Integrative Health (NCCIH)Non ancora reclutamento
-
M.V. Hospital for DiabetesMSD Pharmaceuticals LLCCompletatoVaccino pneumococcicoIndia
-
Medical College of WisconsinAttivo, non reclutante
-
Scripps Whittier Diabetes InstituteReclutamentoDiabete di tipo 2Stati Uniti
-
Hacettepe UniversityCompletatoDiabete di tipo 2Tacchino